Pharmamarketeer

EMA committee recommends to revoke fenspiride marketing authorisations

European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has recommended that the marketing authorisations for fenspiride medicines be revoked, so the medicines can no longer be marketed in the EU.

Advertentie(s)